FDA Approves Dupilumab as First Biologic Treatment for COPD
September 27th 2024The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype to significantly help reduce exacerbations and improve lung function.
Read More
State Policy Opportunities to Control Health Care Prices: A CPR Report
September 25th 2024Catalyst for Payment Reform (CPR) explores stakeholder perspectives in Florida, Michigan, and Nevada, revealing both the challenges and opportunities states face in reforming health care pricing structures.
Read More
A 3-year follow-up of patients with refractory/relapsed indolent non-Hodgkin (NHL) treated with a combination of magrolimab and rituximab showed no new treatment-emergent adverse events, suggesting long-term safety. The treatment also confirmed magrolimab penetration into the tumor.
Read More
House Unanimously Passes Seniors’ Access to Critical Medications Act
September 25th 2024The House of Representatives unanimously passed the bipartisan Seniors’ Access to Critical Medications Act (HR 5526), which would reverse CMS restrictions on mail delivery of cancer medications to Medicare beneficiaries.
Read More
Sacubitril/Valsartan, Enalapril Show Comparable Efficacy in Pediatric Heart Failure
September 25th 2024In the PANORAMA-HF trial, children receiving sacubitril/valsartan for their heart failure experienced clinically meaningful improvements similar to those seen in children receiving enalapril, although the former may provide an edge on quality of life.
Read More
Over Half of US Infants Infected With RSV in First Year of Life, Study Finds
September 25th 2024More than half of healthy term infants born in the United States are infected with respiratory syncytial virus (RSV) during their first year of life, with significant hospitalization and illness rates observed.
Read More
CHMP Recommends Mirvetuximab Soravtansine for FRα+ Ovarian Cancer
September 25th 2024The European Medicines Agency's (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing authorization of mirvetuximab soravtansine (Elahere; AbbVie) for folate receptor alpha–positive (FRα+), platinum-resistant epithelial ovarian cancer.
Read More
Hidradenitis Suppurativa Disproportionately Affects Black, Female Patients
September 25th 2024A poster presented at the Skin of Color Update reported that hidradenitis suppurativa (HS) disproportionately affects Black patients, women, smokers, and those with public insurance or disabilities.
Read More
Korean Study Finds DOAC Use “Seems Effective” in Patients With MPNs
September 25th 2024A study based on a decade's worth of Korean insurance data found that use of direct oral anticoagulants (DOACs) to address atrial fibrillation and venous thromboembolism in patients with myeloproliferative neoplasms (MPNs) is effective, with acceptable bleeding risk.
Read More
Navigating the Rising Costs of Biologics: Strategies for Integrated Delivery Networks
September 25th 2024Strategies for integrated delivery networks (IDNs) to manage rising biologic medication costs while ensuring financial sustainability and patient outcomes are discussed during an interview with Elie M. Bahou, PharmD, MBA, senior vice president and system chief pharmacy officer at Providence.
Read More